Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;33(6):309-318.
doi: 10.1097/MOL.0000000000000849. Epub 2022 Sep 28.

Recent Apolipoprotein CIII trials

Daniele Tramontano  1 , Simone Bini, Laura D'Erasmo, Marcello Arca
Affiliations
Review

Recent Apolipoprotein CIII trials

Daniele Tramontano et al. Curr Opin Lipidol. .

Abstract

Purpose of review: This review will briefly revise the evidence concerning the pharmacological inhibition of Apolipoprotein CIII (ApoCIII) in patients with hypertriglyceridemia.

Recent findings: ApoCIII is a plasma apolipoprotein playing a major role in the metabolism of triglyceride-rich lipoproteins, namely chylomicrons and very-low-density lipoproteins as well as in the pathological processes involved in atherosclerosis. Therefore, ApoCIII is a potential new target for reducing plasma levels of TRLs and, thereby, cardiovascular risk. In recent years, there have been extensive preclinical and clinical pharmacological studies aimed at testing drugs directed against ApoCIII.

Summary: In this review, firstly we will summarize the molecular function of ApoCIII in lipoprotein metabolism. Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.

PubMed Disclaimer

References

    1. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J 2020; 41:99–109c.
    1. Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther 2012; 10:505–514.
    1. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2:655–666.
    1. Belhassen M, Van Ganse E, Nolin M, et al. 10-Year comparative follow-up of familial versus multifactorial chylomicronemia syndromes. J Clin Endocrinol Metab 2021; 106:e1332–e1342.
    1. Simha V. Management of hypertriglyceridemia. BMJ 2020; 371:m3109.

MeSH terms